Eli Lilly and Company (LLY) on Focus After Forming Double Top

Eli Lilly and Company (NYSE:LLY) Logo

Investors sentiment increased to 0.98 in Q3 2018. Its up 0.14, from 0.84 in 2018Q2. It improved, as 37 investors sold Eli Lilly and Company shares while 399 reduced holdings. 141 funds opened positions while 286 raised stakes. 794.28 million shares or 1.80% less from 808.82 million shares in 2018Q2 were reported.
Lsv Asset Management reported 862,829 shares. Motco holds 53,832 shares. Synovus Finance has 0.33% invested in Eli Lilly and Company (NYSE:LLY). Wealth Architects Limited Liability has 2,211 shares. Vision Inc invested in 6,996 shares or 0.2% of the stock. First Citizens Commercial Bank And Communication reported 0.18% stake. Pitcairn owns 4,733 shares or 0.05% of their US portfolio. Foster Dykema Cabot And Incorporated Ma has 0.13% invested in Eli Lilly and Company (NYSE:LLY). American Investment Serv has 0.1% invested in Eli Lilly and Company (NYSE:LLY) for 2,900 shares. Campbell Newman Asset Mngmt holds 0.41% or 26,316 shares. At Savings Bank has invested 0.04% in Eli Lilly and Company (NYSE:LLY). Connors Investor Serv Inc invested in 0.91% or 62,729 shares. Schroder Investment Management Grp has 0.68% invested in Eli Lilly and Company (NYSE:LLY) for 3.70M shares. Alpha Windward Ltd Liability Com holds 3,265 shares or 0.21% of its portfolio. Pure Financial Advisors Inc holds 0.07% or 3,166 shares.

Since July 24, 2018, it had 1 buying transaction, and 27 selling transactions for $354.11 million activity. 25,000 shares were sold by O’Neill Myles, worth $2.82 million. Zulueta Alfonso G sold $637,830 worth of stock. Zakrowski Donald A sold 600 shares worth $63,342. $206,437 worth of stock was bought by TAI JACKSON P on Thursday, July 26.

The chart of Eli Lilly and Company (LLY) shows a double top with $124.83 target or 9.00 % above today’s $114.52 share price. The 5 months chart pattern indicates low risk for the $112.55B company. It was reported on Jan, 14 by Finviz.com. If the $124.83 price target is reached, the company will be worth $10.13 billion more. Double tops are rare but powerful chart patterns.

The stock decreased 1.43% or $1.66 during the last trading session, reaching $114.52. About 410,077 shares traded. Eli Lilly and Company (NYSE:LLY) has risen 32.86% since January 14, 2018 and is uptrending. It has outperformed by 32.86% the S&P500.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on January, 30. They expect $1.37 EPS, up 20.18 % or $0.23 from last year’s $1.14 per share. LLY’s profit will be $1.35B for 20.90 P/E if the $1.37 EPS becomes a reality. After $1.39 actual EPS reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts -1.44 % negative EPS growth.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Among 10 analysts covering Eli Lilly (NYSE:LLY), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Eli Lilly had 16 analyst reports since July 17, 2018 according to SRatingsIntel. The firm earned “Market Perform” rating on Wednesday, October 3 by BMO Capital Markets. The rating was maintained by BMO Capital Markets on Thursday, July 19 with “Market Perform”. Bank of America maintained Eli Lilly and Company (NYSE:LLY) rating on Wednesday, July 25. Bank of America has “Neutral” rating and $94 target. The firm earned “Neutral” rating on Monday, November 26 by Citigroup. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, July 31. Barclays Capital maintained the shares of LLY in report on Tuesday, September 18 with “Overweight” rating. Berenberg downgraded Eli Lilly and Company (NYSE:LLY) on Wednesday, July 25 to “Hold” rating. Credit Suisse maintained it with “Underperform” rating and $86 target in Wednesday, July 25 report. The company was maintained on Friday, September 7 by Barclays Capital. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, July 25 report.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Benzinga.com which released: “Eli Lilly and Company (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) – Eli Lilly Gets Ready For First Report Post-Elanco IPO – Benzinga” on November 05, 2018, also Seekingalpha.com with their article: “Lilly and BI’s T2D med Tradjenta shows CV benefit in large-scale study; LLY up 1% premarket – Seeking Alpha” published on July 19, 2018, 247Wallst.com published: “Eli Lilly Scores Solid Results in Psoriatic Arthritis Study – 24/7 Wall St.” on December 17, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Fool.com and their article: “Here’s Why Loxo Oncology Soared 66.4% in 2018, and Another 66% Since – The Motley Fool” published on January 13, 2019 as well as Fool.com‘s news article titled: “Why Aratana Therapeutics Inc. Is Tumbling Today – Motley Fool” with publication date: January 11, 2019.

Eli Lilly and Company develops, manufactures, and markets pharmaceutical products worldwide. The company has market cap of $112.55 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It has a 263.26 P/E ratio. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.